# Spyre Therapeutics, Inc.: overview

SYRE · Nasdaq · CIK 1636282 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/syre.md) · [Financials](/companies/syre/financials.md) · [Filings](/companies/syre/filings.md) · [Insiders](/companies/syre/insiders.md)

Latest reported revenue: [$0](/filings/0001636282-26-000020.md) for Q4 FY2024, three months to 2024-12-31, from the 10-K filed Feb 19, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001636282-26-000020).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $ | [0.0](/filings/0001636282-24-000113.md) | [0.0 d](/filings/0001636282-26-000020.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [1.06](/filings/0001636282-24-000113.md) | not reported | not reported | not reported | not reported | not reported | [(0.74)](/filings/0001636282-26-000050.md) | not reported |
| Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [18.7](/filings/0001636282-24-000107.md) | [2.3](/filings/0001636282-25-000020.md) | [0.9](/filings/0001636282-26-000020.md) | [0.0](/filings/0001636282-26-000020.md) | [0.0](/filings/0001636282-26-000020.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(350.3%)](/filings/0001636282-24-000107.md) | [(3640.2%)](/filings/0001636282-25-000020.md) | [(27348.0%)](/filings/0001636282-26-000020.md) | not reported | not reported |
| Net margin | % | [(351.1%)](/filings/0001636282-24-000107.md) | [(3598.8%)](/filings/0001636282-25-000020.md) | [(38238.1%)](/filings/0001636282-26-000020.md) | not reported | not reported |
| Diluted EPS | $ per share | [(25.02)](/filings/0001636282-24-000005.md) | [(24.86)](/filings/0001636282-24-000005.md) | [13.76](/filings/0001636282-24-000107.md) | not reported | not reported |
| Free cash flow | $m | [(54.3)](/filings/0001636282-24-000107.md) | [(80.2)](/filings/0001636282-25-000020.md) | [(99.9)](/filings/0001636282-26-000020.md) | [(157)](/filings/0001636282-26-000020.md) | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/syre/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $1.16bn | 13,026,187 |  | Added +1,245,163 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $577.7m | 6,506,605 |  | Added +985,384 |
| [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $383.5m | 4,319,496 |  | Added +536,271 |
| [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $377.5m | 4,251,996 |  | Added +80,000 |
| [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $341.0m | 3,840,778 |  | Added +1,883,512 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $306.2m | 3,448,681 |  | Added +391,280 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $271.4m | 3,057,416 |  | Added +450,385 |
| [Venrock Adviser, LLC](/funds/1615982.md) | 2026-06-30 | $265.0m | 2,985,448 |  | Reduced −700,000 |
| [Driehaus Capital Management LLC](/funds/938206.md) | 2026-06-30 | $248.5m | 2,799,166 |  | Added +8,381 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $239.3m | 2,562,265 |  | Added +841,353 |

## Recent filings

[All 803 filings](/companies/syre/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-09 | 21:00 ET | [SCHEDULE 13D/A](/filings/0001104659-26-115087.md) | Ownership report, active investor, amended | 0001104659-26-115087 |
| 2026-10-07 | 12:00 ET | [8-K](/filings/0001628280-26-065291.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001628280-26-065291 |
| 2026-09-08 | 12:01 ET | [8-K](/filings/0001636282-26-000113.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001636282-26-000113 |
| 2026-08-25 | 20:04 ET | [8-K](/filings/0001636282-26-000105.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001636282-26-000105 |
| 2026-08-04 | 20:05 ET | [8-K](/filings/0001636282-26-000098.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001636282-26-000098 |
| 2026-08-04 | 20:02 ET | [10-Q](/filings/0001636282-26-000096.md) | Quarterly report, period 2026-06-30 | 0001636282-26-000096 |
| 2026-06-23 | 01:45 ET | [SCHEDULE 13D/A](/filings/0001104659-26-076961.md) | Ownership report, active investor, amended | 0001104659-26-076961 |
| 2026-06-15 | 12:01 ET | [8-K](/filings/0001636282-26-000083.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001636282-26-000083 |
| 2026-06-01 | 20:01 ET | [8-K](/filings/0001636282-26-000075.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001636282-26-000075 |
| 2026-05-29 | 20:45 ET | [8-K](/filings/0001636282-26-000056.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001636282-26-000056 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001636282-26-000020.md), filed Feb 19, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1636282
- Tickers: SYRE
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.